Biogen Idec Chief George Scangos Among 25 Most Influential People in Biopharma … – Citybizlist (press release)
 Citybizlist (press release) | Biogen Idec Chief George Scangos Among 25 Most Influential People in Biopharma ... Citybizlist (press release) based company's "stock took off last year, fueled by positive data on key experimental therapies such as the multiple sclerosis pill BG-12 and the long-acting MS treatment daclizumab," the report said, saying Scangos "has refocused the company's R&D ... |
Helmut-Bauer-Nachwuchspreis 2011 für Multiple-Sklerose-Forschung – DMSG Multiple Sklerose Nachrichten
Helmut-Bauer-Nachwuchspreis 2011 für Multiple-Sklerose-Forschung DMSG Multiple Sklerose Nachrichten Die Arbeit von Dr. Simone Wüst wurde prämiert, weil sie im Detail die Wirkung des monoklonalen Antikörpers Daclizumab bei der T-Zellaktivierung Der 23-jährige Preisträger cand. med. Lukas Haider ist derzeit als PhD Student in der Abteilung ... |
George Scangos – The 25 most influential people in biopharma today – FierceBiotech
George Scangos - The 25 most influential people in biopharma today FierceBiotech The Weston, MA-based company's stock took off last year, fueled by positive data on key experimental therapies such as the multiple sclerosis pill BG-12 and the long-acting MS treatment daclizumab. Those programs predate Scangos' arrival, ... |
Biogen Idec’s CEO Discusses Q4 2011 Results – Earnings Call Transcript – Seeking Alpha
Biogen Idec's CEO Discusses Q4 2011 Results - Earnings Call Transcript Seeking Alpha SELECT, the first of 2 registrational trials for Daclizumab, showed impressive clinical results in 2011 and supported the continuation of the second registrational study, DECIDE. We also completed enrollment for ADVANCE, our Phase III trial, ... |
The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs … – Sacramento Bee
The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs ... Sacramento Bee Abbott Labs, along with partner Biogen (Nasdaq: BIIB), moved daclizumab into a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Abbott Labs is also working on an intestinal gel for advanced Parkinson's disease – the ... |
The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs … – NASDAQ
The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs ... NASDAQ Abbott Labs, along with partner Biogen ( BIIB ), moved daclizumab into a phase III study for the treatment of relapsing-remitting multiple sclerosis ( RRMS ). Abbott Labs is also working on an intestinal gel for advanced Parkinson's disease - the ... |
The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs … – PR Newswire (press release)
The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs ... PR Newswire (press release) Abbott Labs, along with partner Biogen (Nasdaq: BIIB), moved daclizumab into a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Abbott Labs is also working on an intestinal gel for advanced Parkinson's disease – the ... |
Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in Fourth … – MarketWatch (press release)
Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in Fourth ... MarketWatch (press release) Presented New Daclizumab Data at Multiple Sclerosis Congress Announced with our partner company Biogen Idec additional results from the SELECT Phase 2b trial, the first of two registrational studies designed to evaluate daclizumab high-yield process ... |
Newly Released BioTrends Chart Audit Report Identifies Variations in Treatment … – EON: Enhanced Online News (press release)
Newly Released BioTrends Chart Audit Report Identifies Variations in Treatment ... EON: Enhanced Online News (press release) Patient profiles for the seven DMAs in late clinical development (alemtuzumab, BG-12, teriflunomide, laquinimod, PEG-Avonex, daclizumab, ocrelizumab) are also characterized. BioTrends Research Group, LLC provides syndicated and custom market research ... |
Newly Released BioTrends Chart Audit Report Identifies Variations in Treatment … – MarketWatch (press release)
Newly Released BioTrends Chart Audit Report Identifies Variations in Treatment ... MarketWatch (press release) Patient profiles for the seven DMAs in late clinical development (alemtuzumab, BG-12, teriflunomide, laquinimod, PEG-Avonex, daclizumab, ocrelizumab) are also characterized. BioTrends Research Group, LLC provides syndicated and custom market research ... |